Hypertension and Treatment Comparisons in CLL Management

This chapter examines hypertension as a side effect in patients being treated for chronic lymphocytic leukemia, focusing on the impacts of various drugs like acalabrutinib and zanabrutinib. It also highlights findings from the Amplify trial regarding long-term outcomes with venetoclax and the significance of consistent blood pressure monitoring during treatment.